The Usefulness of the ASSUSTENT Application and ASSIST Brochure in Cancer Patients Using Sunitinib

Purpose of ResearchThe ASSUSTENT application and the ASSIST brochure have been developed to support medication intake and symptom monitoring. This study aimed to evaluate patient experiences and the factors that are a barrier to or facilitate the use of these tools. Additionally, the effect of their use on Health-Related Quality of Life (HRQoL) and satisfaction with information about medication was also assessed.MethodsAn exploratory study with a mixed method design was performed. Patients starting or already using sunitinib were asked to use the application or the brochure for 6 months. They completed questionnaires about their experiences with the intervention, that is, the Satisfaction with Information about Medication scale (SIMS) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline (T0), three months (T1), and 6 months (T2) following inclusion. Patients were also asked to participate in a semi-structured interview at T2. The main study endpoint was the feasibility of the use of the application and the brochure.ResultsOf the 22 (65%) patients who signed the informed consent, 19 (86%) completed T0, 15 (68%) T1, and 12 (54%) T2. Twelve agreed to be interviewed. Both the application and brochure were considered user friendly and useful to manage symptoms and prepare for consultations. Patients were generally satisfied with the information about medication. The mean global HRQoL increased from 69 (T0) to 84 (T2).ConclusionAs supplements to usual care, both the application and the brochure met the needs of cancer patients using sunitinib. Their use led to an increased self-efficacy in managing symptoms. The availability of the brochure adds to patient-centered care and equal access to care, and increases self-efficacy.